Important Updates! This coming Monday will be the Big Day of our 2024 BRACE Award Venture Competition. We are thrilled to announce the 3 Semi-Finalists competing this year, selected from a pool of 41 applications submitted by early-stage oncology companies from 10 different countries worldwide!

Congratulations to these outstanding scientist-entrepreneurs and their companies:

  • Concarlo Therapeutics | Stacy Blain, Ph.D. | Founder & CEO
  • NexCalibur Therapeutics | Minh-Duy Phan, Ph.D. | CEO & Scientific Co-Founder
  • Orphagen Pharmaceuticals | Scott Thacher, Ph.D. | CEO

The 2024 BRACE Award Venture Competition is launched in collaboration with our partner organization, the Asian Fund for Cancer Research (AFCR), to accelerate innovative technologies that address cancers prevalent in underserved populations.

We would like to extend our heartful thanks to the selection and judging committee members for their tremendous support of the competition and invaluable contributions. We also want to say thank you to all of our dear supporters for helping advance that cause!

About the AIM-HI Accelerator Fund

The AIM-HI Accelerator Fund (AIM-HI) is a 501(c)(3) nonprofit organization established in 2019 with an initial capacity-building grant from the National Foundation for Cancer Research to accelerate the translation of cancer drug discoveries by investing in seed-stage oncology companies. AIM-HI Accelerator Fund bridges the gap between innovative cancer discoveries and high-impact cancer treatments and technologies and facilitates an ecosystem for early-stage companies and entrepreneurs. To learn more about the AIM-HI Accelerator Fund, visit AIM-HIAccelerator.org.

About the National Foundation for Cancer Research

The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization co-founded in 1973 by Nobel Laureate Dr. Albert Szent-Györgyi and Attorney/Business Entrepreneur Franklin Salisbury, Sr. NFCR provides scientists in the lab with the critical seed funding they need to make game-changing discoveries in cancer detection, treatments, prevention, and ultimately, a cure for all cancers. NFCR has distinguished itself in the cancer research sector by emphasizing “high-risk, high-impact” long-term and transformative pioneering research fields often overlooked by other major funding sources. With the support of more than 5.3 million individual donors over the last 50+ years, NFCR has provided more than $415 million in funding to cancer research, prevention, and public education. NFCR-supported research has led to some of the most significant life-saving discoveries that benefit patients today.